Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Amid more job cuts, AZ brings on GSK's Dunoyer as business chief

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...

Chimerix picks up Michael Rogers, unveils $85M IPO plan

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...

Pharmaxis gets new CEO in shakeup

Facing down a recent FDA advisory committee vote against Bronchitol, Australia's Pharmaxis says that it has found a new CEO and is reviewing its business strategy.

Reports: Ex-Novartis chief Vasella to flee Switzerland for US

Swiss media report that Vasella is decamping from his home in Zug for greener pastures in the U.S.

Roche chairman steps down

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...

Aastrom lands a new CEO in a game of musical biotech chairs

Shares of Aastrom bounced higher yesterday as biotech veteran Dominick Colangelo was named the new CEO, taking the reins during a crucial pivotal study of the company's personalized cell therapy.

Ex-Amgen research czar Perlmutter to helm Merck's struggling R&D ops

Roger Perlmutter is back. About a year after the Amgen R&D chief was squeezed out in a top-level reshuffling at the big biotech, Merck says they have tapped him to run the Big Pharma's research house, which has been consuming $8 billion a year without a lot to show for it.

Shocking exit bonus for a departing chief? Not us, Roche says

Outgoing Roche Chairman Franz Humer will get a bonus when he leaves next year, Vice Chairman Andre Hoffman told shareholders. But it will be "completely different" from the $76 million fellow Swiss drugmaker Novartis originally planned to pay ex-chairman Daniel Vasella.

Longtime Roche chairman is stepping aside. Who's up next?

There will be room at the top of Roche next year. Chairman Franz Humer will stand down after the Swiss drugmaker's 2014 annual meeting, after 16 years as CEO or chairman or both. The company plans to pick a successor by autumn.

Endo names Rajiv De Silva president, CEO

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...